No Data
No Data
ReproCELL: Half-Year Report - Term 23 (2024/04/01－2025/03/31)
ReproCELL: Confirmation letter
ReproCELL: 2nd Half (Mid-Term) Decision SMS for March 2025 [Japan Basis] (link)
Medrek, Replcell, and others
Dream Vision's 11th subscription rights (with exercise price adjustment clause) will issue a large amount of shares starting from the 28th, with 0.5 million shares. MedRx MRX-7MLL <4586> has started clinical trials. OncoLis Bio's 20th subscription rights (with exercise price adjustment clause) will issue a large amount of shares starting from the 18th, with 0.512 million shares. Progress of clinical phases 1/2 trials for DELTA-PDF-10917 and VEN <4598>. Modalis's 14th subscription rights.
Supported by a firm US stock market, but there may be a heavy resistance to price increases.
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to show a firm performance. In the U.S. stock market on the 16th, the Dow Jones Industrial Average rebounded by 337.28 points (+0.79%) to 43,077.70 points. The positive earnings reports from airlines and financial companies, as well as the stock price increase of the semiconductor company Nvidia (NVDA), have improved investor sentiment. Expectations for a soft landing and the decline in long-term interest rates have also supported stock prices. It seems that buying will dominate today's emerging markets. Major indices rose in the U.S. stock market yesterday.
Deere & Co, RepliCel, and others [Emerging Markets Press Release]
Following the company split (simplified establishment split) at <155A>, a subsidiary was established. At <3935>, deere & co requested a market change to the Tokyo Stock Exchange's standard market. At <4978>, Cell AMED received approval for the market change. The grant amount for the 2023 fiscal year for the Public Offering Business 'Basic Technology Development Project for Industrialization of Regenerative Medicine and Gene Therapy' has been determined.
No Data
No Data